Adverse Events And Quality Of Life In Advanced Parkinson'S Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel Infusion Therapy

Background: Levodopa-carbidopa intestinal gel infusion therapy (LCIG) is a standard device-aided treatment for advanced Parkinson's disease (APD). The aim of our study was to retrospectively assess the adverse effects (AE) related to LCIG and the change of patients' health-related quality of life (HRQoL) after LCIG.